Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Blesl, A; Krones, E; Pollheimer, MJ; Haybaeck, J; Wiesspeiner, U; Lipp, RW; Kump, P.
Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology?
Case Rep Oncol. 2018; 10(3):1121-1126 Doi: 10.1159/000484473 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Blesl Andreas
Kump Patrizia
Co-Autor*innen der Med Uni Graz
Haybäck Johannes
Lipp Rainer
Pollheimer Marion
Tatscher Elisabeth
Wießpeiner Ulrike Josefine

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

The antiproliferative treatment options for neuroendocrine tumors (NET)/neuroendocrine carcinomas of the gastrointestinal tract critically depend on the proliferation rate, evaluated by immunohistochemical staining for Ki-67. According to their grading, tumors are treated with somatostatin analogs, mTOR inhibitors, or cytotoxic substances. This case illustrates downgrading of a primarily highly proliferative NET achieved by a variation of cytotoxic chemotherapy regimens, followed by a combination therapy using everolimus together with lanreotide. The latter medication might lead to a good clinical response as far as tumor growth is concerned.

Find related publications in this database (Keywords)
Neuroendocrine tumor
Liver biopsy
© Med Uni Graz Impressum